glp 1 in obesity Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss Glucagon-Like Peptide-1 Based Therapies: A

doi: 10.1007/s11154-007-9025-5 68 SharmaRKopchickJJPuriVSharmaVM

The causal mechanisms may vary and are less well understood than in celiac disease

By Lana Pine | Published on December 17, 2025 4 min read A large real-world study published in Neurology found that people with Type 2 diabetes taking glucagon-like peptide-1 (GLP-1) receptor agonists had a lower risk of developing epilepsy than those taking dipeptidyl peptidase-4 (DPP-4) inhibitors

10.1016/j.cmet.2012.04.003 90 QiaoS.KangY.TanX.ZhouX.ZhangC.LaiS.et al (2024)

Retatrutide is an investigational triple agonist (GLP-1/GIP/glucagon) that has shown even greater weight loss than tirzepatide in early trials (up to 24% body weight reduction)